Emergent shortages of the drug used to treat the most severe form of African sleeping sickness creates immediate need for direct access to the global drug market for affected nationsAs previously reported, PaxMedica recently executed final registration and validation batches of PAX-101 (an IV form of suramin) in preparation for a future NDA submission as an orphan designated drug TARRYTOWN, New York, April 16, 2024 (GLOBE NEWSWIRE) -- via IBN -- PaxMedica, Inc. (NASDAQ: PXMD), a biopharmaceutica
TARRYTOWN, New York, April 11, 2024 (GLOBE NEWSWIRE) -- via IBN – PaxMedica, Inc. (NASDAQ:PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, today announced the completed execution of its three pivotal registration/validation batches of PAX-101, an IV formulation of suramin. This achievement is an important milestone to enabling a New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA), which is currently planned for Q4 202
TARRYTOWN, New York, March 13, 2024 (GLOBE NEWSWIRE) -- via IBN – PaxMedica, Inc. (NASDAQ:PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, today announced the release of its latest company presentation. This comprehensive overview showcases PaxMedica’s strategic direction, recent advancements in ASD therapeutics, and its commitment to addressing unmet needs within the ASD community. Click here to view the presentation. The new presentation, available